63 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 29, No 3, May/June 2018
AFRICA
193
298–304.
8.
Boehncke WH, Schon MP. Psoriasis.
Lancet
2015;
386
(9997): 983–994.
9.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic
syndrome: a systematic review and meta-analysis of observational studies.
J Am Acad Dermatol
2013;
68
(4): 654–662.
10. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB.
Risk of myocardial infarction in patients with psoriasis.
J Am Med Assoc
2006;
296
(14): 1735–1741.
11. Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoria-
sis.
Acta Dermatovenerol Croat
2010;
18
(4): 297–304.
12. Kim J, Krueger JG. The immunopathogenesis of psoriasis.
Dermatol Clin
2015;
33
(1): 13–23.
13. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta
NN,
et al
. Prevalence of metabolic syndrome in patients with psoriasis: a
population-based study in the United Kingdom.
J Invest Dermatol
2012;
132
(3 Pt 1): 556–562.
14. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of
moderate to advanced kidney disease in patients with psoriasis: population
based cohort study.
Br Med J
2013;
347
: f5961.
15. Armstrong AW, Harskamp CT, Armstrong EJ. The association between
psoriasis and obesity: a systematic review and meta-analysis of observa-
tional studies.
Nutr Diabetes
2012;
2
: e54.
16. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A,
et al
.
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-
based case-control study.
Br J Dermatol
2007;
157
(1): 68–73.
17. Henseler T, Christophers E. Disease concomitance in psoriasis.
J Am Acad
Dermatol
1995; 32(6): 982–986.
18. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with
lipid abnormalities at the onset of skin disease.
J Am Acad Dermatol
2006;
54
(4): 614–621.
19. Ahlehoff O, Gislason GH, Jorgensen CH, Lindhardsen J, Charlot M,
Olesen JB,
et al
. Psoriasis and risk of atrial fibrillation and ischaemic
stroke: a Danish Nationwide Cohort Study.
Eur Heart J
2012;
33
(16):
2054–2064.
20. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X,
et
al
. The risk of stroke in patients with psoriasis.
J Invest Dermatol
2009;
129
(10): 2411–2418.
21. Khalid U, Egeberg A, Ahlehoff O, Smedegaard L, Gislason GH, Hansen
PR. Nationwide study on the risk of abdominal aortic aneurysms in
patients with psoriasis.
Arterioscler Thromb Vasc Biol
2016;
36
(5): 1043–
1048.
22. Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between
non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis?
Int J Mol Sci
2016;
17
(2): 217–229.
23. Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricemia in patients
with chronic plaque psoriasis.
J Am Acad Dermatol
2014;
70
(1): 127–130.
24. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham
A,
et al
. Identification of a major susceptibility locus on chromosome 6p
and evidence for further disease loci revealed by a two stage genome-wide
search in psoriasis.
Hum Mol Genet
1997;
6
(5): 813–820.
25. Nestle FO, Kaplan DH, Barker J. Psoriasis.
N Engl J Med
2009;
361
(5):
496–509.
26. Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J,
Olesen JB,
et al
. Psoriasis is associated with clinically significant cardiovas-
cular risk: a Danish nationwide cohort study.
J Intern Med
2011;
270
(2):
147–157.
27. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse
cardiovascular events: a systematic review and meta-analysis of observa-
tional studies.
J Am Heart Assoc
2013;
2
(2): e000062.
28. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH.
Incidence of cardiovascular disease in individuals with psoriasis: a system-
atic review and meta-analysis.
J Invest Dermatol
2013;
133
(10): 2340–2346.
29. Reich K. The concept of psoriasis as a systemic inflammation: implications
for disease management.
J Eur Acad Dermatol Venereol
2012;
26
(Suppl 2):
3–11.
30. Libby P, Ridker PM, Hansson GK, Leducq A. Transatlantic network on
inflammation in atherosclerosis: from pathophysiology to practice.
J Am
Coll Cardiol
2009;
54
(23): 2129–2138.
31. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation
2002;
105
(9): 1135–1143.
32. Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M.
Cardiovascular risk in rheumatoid arthritis: recent advances in the under-
standing of the pivotal role of inflammation, risk predictors and the impact
of treatment.
Rheumatology
2014;
53
(12): 2143–2154.
33. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A.
Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-
analysis.
Joint Bone Spine
2011;
78
(2): 179–183.
34. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: model of
systemic inflammation driving atherosclerosis.
Circ J
2009;
73
(6): 977–985.
35. Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: poten-
tial mechanisms and solutions.
Curr Opin Rheumatol
2005;
17
(3): 286–292.
36. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a
concept of how severe psoriasis may drive cardiovascular comorbidity.
Exp
Dermatol
2011;
20
(4): 303–307.
37. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients.
N Engl J Med
1973;
288
(17): 912.
38. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease.
Br J
Dermatol
1978;
99
(5): 469–475.
39. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in
patients with psoriasis: 10 years prospective experience in a cohort of 1,380
patients.
J Invest Dermatol
1988;
91
(3): 197–201.
40. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent
risk factor for acute ischemic heart disease hospitalizations: results of a
large population-based Dutch cohort.
J Invest Dermatol
2010;
130
(4):
962–967.
41. Dowlatshahi EA, Kavousi M, Nijsten T, Ikram MA, Hofman A, Franco
OH,
et al.
Psoriasis is not associated with atherosclerosis and incident
cardiovascular events: the Rotterdam Study.
J Invest Dermatol
2013;
133
(10): 2347–2354.
42. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of
diabetes mellitus: a systematic review and meta-analysis.
J Am Med Assoc
Dermatol
2013;
149
(1): 84–91.
43. Armstrong AW, Lin SW, Chambers CJ, Sockolov ME, Chin DL. Psoriasis
and hypertension severity: results from a case-control study.
PLoS One
2011;
6
(3): e18227.
44. Sterry W, Strober BE, Menter A, International Psoriasis C. Obesity in
psoriasis: the metabolic, clinical and therapeutic implications. Report of
an interdisciplinary conference and review.
Br J Dermatol
2007;
157
(4):
649–655.
45. Janssen I, Katzmarzyk PT, Ross R. Body mass index, waist circumference,
and health risk: evidence in support of current National Institutes of
Health guidelines.
Arch Intern Med
2002;
162
(18): 2074–2079.
46. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight
change, and the risk of psoriasis in women: Nurses’ Health Study II.
Arch
Intern Med
2007;
167
(15): 1670–1675.
47. Balci A, Balci DD, Yonden Z, Korkmaz I, Yenin JZ, Celik E,
et al
.
Increased amount of visceral fat in patients with psoriasis contributes to
metabolic syndrome.
Dermatology
2010;
220
(1): 32–37.
48. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association
between psoriasis and dyslipidaemia: a systematic review.
Br J Dermatol